CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)

Impact Biomedical Inc (NYSE: IBO) announced a 1 for 12.62 reverse stock split effective September 23, 2026, to support its proposed merger with Zoar Limited. The merger exchange ratio was corrected to 1 share of Zoar for every 1 share of Impact stock (post-split). Upon completion, the combined entity will focus on developing and supplying Active Pharmaceutical Ingredients for special therapeutic areas.